TickerFacts.

Harrow, Inc. (HROW): Cash & Equivalents

Annual figures by period end, from SEC filings.

$72.93M
As of 2025-12-31
$83.89M
As of 2026-06-30
-8.8%
3-year compound annual growth
+77.8%
5-year compound annual growth
+39.1%
10-year compound annual growth
$96.27M2009-12-31: $1.59M2010-12-31: $291.5K2011-12-31: $146.2K2012-12-31: $10.04M2013-12-31: $15.58M2014-12-31: $8.21M2015-12-31: $2.69M2016-12-31: $8.85M2017-12-31: $4.02M2019-12-31: $4.75M2020-12-31: $4.10M2021-12-31: $42.17M2022-12-31: $96.27M2023-12-31: $74.08M2024-12-31: $47.25M2025-12-31: $72.93M$72.93M
2009-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$72.93M+54.4%2026-03-02, Balance as of period end
2024-12-31$47.25M-36.2%2026-03-02, Balance as of period end
2023-12-31$74.08M-23.0%2025-03-27, Balance as of period end
2022-12-31$96.27M+128.3%2024-03-19, Balance as of period end
2021-12-31$42.17M+928.2%2022-03-10, Balance as of period end
2020-12-31$4.10M-13.6%2022-03-10, Balance as of period end
2019-12-31$4.75Mn/a2021-03-08, Balance as of period end
No annual figure between 2017-12-31 and 2019-12-31.
2017-12-31$4.02M-54.6%2018-03-08, Balance as of period end
2016-12-31$8.85M+229.7%2018-03-08, Balance as of period end
2015-12-31$2.69M-67.3%2017-03-21, Balance as of period end
2014-12-31$8.21M-47.3%2016-03-23, Balance as of period end
2013-12-31$15.58M+55.2%2015-03-12, Balance as of period end
2012-12-31$10.04Mn/m2014-03-28, Balance as of period end
2011-12-31$146.2K-49.9%2014-03-28, Balance as of period end
2010-12-31$291.5K-81.7%2013-03-18, Balance as of period end
2009-12-31$1.59Mn/a2012-02-23, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Harrow, Inc. (HROW)2025-12-31$72.93M+54.4%
Ligand Pharmaceuticals Inc (LGND)2025-12-31$174.93M+141.9%
Arvinas, Inc. (ARVN)2025-12-31$142.90M+42.2%
Schrodinger, Inc. (SDGR)2025-12-31$230.52M+56.5%
Xeris Biopharma Holdings, Inc. (XERS)2025-12-31$111.04M+55.0%
Ironwood Pharmaceuticals Inc (IRWD)2025-12-31$215.46M+143.3%
Evolus, Inc. (EOLS)2025-12-31$53.83M-38.1%
Arcus Biosciences, Inc. (RCUS)2025-12-31$222.00M+48.0%
Keros Therapeutics, Inc. (KROS)2025-12-31$287.42M-48.7%

Compare HROW, LGND, ARVN, SDGR side by side · Screen every company in Pharmaceutical Preparations ↗